Other studies have reported protective effects related to HO-1 expression after the exogenous administration of CORM in different experimental models of autoimmune diseases, including multiple sclerosis [63], type-1 diabetes [64], and autoimmune hepatitis [65]. Here, HMOX1 is linked to type 1 diabetes mellitus.